| Biological Sciences | Lifetime | 90 | CH 1 | 99.99 |
| Biological Sciences | 2021-2025 | 578 | CH 2 | 99.39 |
| Molecular Medicine | Lifetime | 1 | CH 1 | 99.97 |
| Endocrinology | Lifetime | 9 | CH 1 | 99.87 |
| Clinical Pharmacology | Lifetime | 169 | CH 3 | 99.33 |
| Pollution | Lifetime | 205 | CH 6 | 98.82 |
| Infectious Diseases | Lifetime | 526 | CH 12 | 97.94 |
| Clinical Biochemistry | Lifetime | 259 | CH 7 | 95.47 |
| Applied Microbiology and Biotechnology | Lifetime | 80 | CH 4 | 95.33 |
| Molecular Medicine | 2021-2025 | 14 | CH 2 | 98.89 |
| Clinical Pharmacology | 2021-2025 | 89 | CH 1 | 96.90 |
| Endocrinology | 2021-2025 | 41 | CH 4 | 91.14 |
| Antibiotic Resistance in Bacteria | Lifetime | 1 | CH 1 | 99.99 |
| Antibiotics Pharmacokinetics and Efficacy | Lifetime | 2 | CH 1 | 99.96 |
| Pharmaceutical and Antibiotic Environmental Impacts | Lifetime | 2 | CH 1 | 99.97 |
| Bacterial biofilms and quorum sensing | Lifetime | 3 | CH 1 | 99.95 |
| Enterobacteriaceae and Cronobacter Research | Lifetime | 1 | CH 1 | 99.97 |
| Infections and bacterial resistance | Lifetime | 1 | CH 1 | 99.98 |
| Vibrio bacteria research studies | Lifetime | 4 | CH 1 | 99.95 |
| Antibiotic Use and Resistance | Lifetime | 29 | CH 3 | 99.69 |
| Bacterial Identification and Susceptibility Testing | Lifetime | 40 | CH 2 | 99.68 |
| Tuberculosis Research and Epidemiology | Lifetime | 282 | CH 7 | 98.89 |
| Plant Pathogenic Bacteria Studies | Lifetime | 125 | CH 5 | 98.67 |
| Pneumonia and Respiratory Infections | Lifetime | 272 | CH 6 | 99.00 |
| Bacterial Genetics and Biotechnology | Lifetime | 239 | CH 4 | 98.93 |
| Escherichia coli research studies | Lifetime | 174 | CH 3 | 98.43 |
| Bacteriophages and microbial interactions | Lifetime | 620 | CH 13 | 98.11 |
| Antimicrobial Resistance in Staphylococcus | Lifetime | 349 | CH 8 | 98.36 |
| Urinary Tract Infections Management | Lifetime | 302 | CH 4 | 97.86 |
| Mycobacterium research and diagnosis | Lifetime | 600 | CH 13 | 97.25 |
| Infectious Disease Case Reports and Treatments | Lifetime | 35 | CH 1 | 96.40 |
| Pneumocystis jirovecii pneumonia detection and treatment | Lifetime | 535 | CH 15 | 97.37 |
| Salmonella and Campylobacter epidemiology | Lifetime | 519 | CH 8 | 97.14 |
| Nephrotoxicity and Medicinal Plants | Lifetime | 345 | CH 7 | 81.76 |
| Actinomycetales infections and treatment | Lifetime | 881 | CH 12 | 71.03 |
| Antibiotic Resistance in Bacteria | 2021-2025 | 37 | CH 2 | 99.29 |
| Antibiotics Pharmacokinetics and Efficacy | 2021-2025 | 22 | CH 1 | 99.00 |
| Pharmaceutical and Antibiotic Environmental Impacts | 2021-2025 | 124 | CH 2 | 97.49 |
| Enterobacteriaceae and Cronobacter Research | 2021-2025 | 13 | CH 1 | 95.31 |
| Antibiotic Use and Resistance | 2021-2025 | 163 | CH 5 | 96.01 |
| Vibrio bacteria research studies | 2021-2025 | 84 | CH 3 | 94.15 |
| Bacterial biofilms and quorum sensing | 2021-2025 | 190 | CH 7 | 93.10 |
| Pneumonia and Respiratory Infections | 2021-2025 | 363 | CH 8 | 93.22 |
| Bacterial Identification and Susceptibility Testing | 2021-2025 | 333 | CH 9 | 90.33 |
| Urinary Tract Infections Management | 2021-2025 | 528 | CH 11 | 83.50 |
| Pneumocystis jirovecii pneumonia detection and treatment | 2021-2025 | 874 | CH 27 | 77.84 |
| Infections and bacterial resistance | 2021-2025 | 111 | CH 2 | 74.71 |
| Escherichia coli research studies | 2021-2025 | 674 | CH 13 | 68.61 |
